At the convalescent time point, serum GFAP concentrations were no higher than controls irrespective of disease severity, but serum NfL concentrations persisted at levels that were higher in patients who had developed moderate and severe COVID-19 compared with controls (Fig. 1C and Supplementary Table 1). The gene discussed is NEFL; the disease is COVID-19.